Sorafenib is a multi-kinase inhibitor that inhibits the activity of vascular endothelial growth factor receptor (VEGFR) and the platelet-derived growth factor receptor (PDGFR) and reduce the formation of new blood vessels in HCC tumors. This evidence concerns the gene PDGFRB and hepatocellular carcinoma.